6-KThe Wire
Innate Pharma SA files 6-K
Filed May 13, 2026 · 1mo ago · Accession 0001628280-26-034383
Plain English
Innate Pharma announced its first quarter 2026 financial results, reporting revenue of €24.6 million and a net loss of €29.1 million. The company also provided an update on its clinical development programs and strategic partnerships.
Filing details
- Company
- Innate Pharma SA
- Ticker
- IPHA
- CIK
- 1598599
- Form type
- 6-K
- Filing date
- May 13, 2026
- Report date
- May 13, 2026
- Document
- a2605136kincorporatediph.htm
- Size
- 45 KB